Anticorps Recombinant de lapin anti-TNFSF11

TNFSF11 Recombinant Antibody for WB, IHC, Indirect ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

souris

Applications

WB, IHC, Indirect ELISA

Conjugaison

Non conjugué

CloneNo.

241791B7

N° de cat : 84431-5-PBS

Synonymes

241791B7, CD254, ODF, OPGL, Osteoclast differentiation factor



Informations sur le produit

84431-5-PBS cible TNFSF11 dans les applications de WB, IHC, Indirect ELISA et montre une réactivité avec des échantillons souris

Réactivité souris
Hôte / Isotype Lapin / IgG
Clonalité Recombinant
Type Anticorps
Immunogène TNFSF11 Protéine recombinante Eg1956
Nom complet tumor necrosis factor (ligand) superfamily, member 11
Masse moléculaire calculée35KD
Poids moléculaire observé22 kDa
Numéro d’acquisition GenBankNM_011613.3
Symbole du gène Tnfsf11
Identification du gène (NCBI) 21943
Conjugaison Non conjugué
Forme Liquide
Méthode de purification Protein A purfication
Tampon de stockage PBS only
Conditions de stockageStore at -80°C. 20ul contiennent 0,1% de BSA.

Informations générales

TNFSF11, known as Tumor Necrosis Factor Superfamily Member 11, also known as RANKL (Receptor Activator of Nuclear Factor-κB Ligand), TRANCE, etc., is a member of the Tumor Necrosis Factor (TNF) superfamily.RANKL is a type II homotrimeric transmembrane protein located primarily at the plasma membrane. RANKL is a type II homotrimeric transmembrane protein located mainly at the plasma membrane, and in addition to the membrane-bound form (mRNAKL), it can also be cleaved by proteolytic cleavage of the cell membrane to produce the soluble form (sRANKL). The membrane-bound form of RANKL is the main form involved in triggering the RANKL/RANK signaling pathway and mediating osteoclastogenesis. Current studies have shown that TNFSF11 acts primarily in the immune and skeletal systems and has been implicated in the pathogenesis of degenerative bone diseases, carcinogenesis, and asthma.

{{ptg:RelatedPrimaryAntibodies}}